{"schema_version":"secwatch.filing_event.v1","accession":"0001448431-25-000010","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.012515+00:00","generated_at":"2026-05-17T17:22:20.942449+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OptimizeRx Q2 revenue $29.2M (+55% YoY); raises FY guidance to $104M-$108M","bullets":["Q2 GAAP net income $1.5M ($0.08/share) vs net loss of $4.0M ($0.22) YoY.","Adjusted EBITDA $5.8M vs $0.5M YoY; non-GAAP net income $4.5M ($0.24 diluted).","Q2 gross profit $18.6M, up 59% YoY; revenue growth driven by deeper pharma partnerships.","Paid down $4.5M of principal on term loan during Q2, $4.0M above required schedule.","FY 2025 guidance raised: revenue $104M-$108M, adjusted EBITDA $14.5M-$17.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001448431-25-000010","json":"https://secwatch.observer/filing/0001448431-25-000010.json","markdown":"https://secwatch.observer/filing/0001448431-25-000010.md","text":"https://secwatch.observer/filing/0001448431-25-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000144843125000010/0001448431-25-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000144843125000010/oprx-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:22:20.942449+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}